Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma Reply

被引：1

作者：

Ambrose, Christopher S. ^{[1
]}

Israel, Elliot ^{[5
]}

Bowen, Karin ^{[2
]}

Llanos, Jean-Pierre ^{[6
]}

Martin, Neil ^{[9
,10
]}

Cook, Bill ^{[1
]}

Hellqvist, Asa ^{[11
]}

Korn, Stephanie ^{[12
,13
]}

Menzies-Gow, Andrew ^{[9
,14
]}

Roseti, Stephanie L. ^{[3
]}

Molfino, Nestor A. ^{[7
]}

Griffiths, Janet M. ^{[4
]}

Parnes, Jane R. ^{[8
]}

机构：

[1] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[2] AstraZeneca, Late Stage Dev, Biometr, Gaithersburg, MD USA

[3] AstraZeneca, Late Stage Dev, Gaithersburg, MD USA

[4] AstraZeneca, Res & Early Dev, Resp & Immunol, BioPharmaceut R&D,Translat Sci & Expt Med, Gaithersburg, MD USA

[5] Harvard Med Sch, Brigham & Womens Hosp, Pulm & Crit Care Med Allergy Immunol, Boston, MA USA

[6] Global Med Affairs, Thousand Oaks, CA USA

[7] Global Dev, Thousand Oaks, CA USA

[8] Amgen Inc, Translat Med, Thousand Oaks, CA USA

[9] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Cambridge, England

[10] Univ Leicester, Leicester, Leics, England

[11] AstraZeneca, Biomet Late Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden

[12] IKF Pneumol Mainz, Mainz, Germany

[13] Thoraxklin Heidelberg, Heidelberg, Germany

[14] Royal Brompton & Harefield Hosp, London, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 208卷 / 02期

关键词：

D O I：

10.1164/rccm.202305-0843LE

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：212 / 213

页数：3

共 6 条

[1]

Brusselle G, 2023, AM J RESP CRIT CARE, V208, P1

[2] Consequences of severe asthma exacerbations [J].

Busse, William W. .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 23 (01) :44-50

[3] Determinants of asthma control and exacerbations in moderate to severe asthma [J].

Chan, Rory ;

Lipworth, Brian J. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (10) :2858-+

[4] Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials [J].

Corren, Jonathan ;

Menzies-Gow, Andrew ;

Chupp, Geoffrey ;

Israel, Elliot ;

Korn, Stephanie ;

Cook, Bill ;

Ambrose, Christopher S. ;

Hellqvist, Asa ;

Roseti, Stephanie L. ;

Molfino, Nestor A. ;

Llanos, Jean-Pierre ;

Martin, Neil ;

Bowen, Karin ;

Griffiths, Janet M. ;

Parnes, Jane R. ;

Colice, Gene .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (01) :13-24

[5] Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond [J].

Corren, Jonathan ;

Brightling, Christopher E. ;

Boulet, Louis-Philippe ;

Porsbjerg, Celeste ;

Wechsler, Michael E. ;

Menzies-Gow, Andrew ;

Ambrose, Christopher S. ;

Cook, Bill ;

Martin, Neil ;

Spahn, Joseph ;

Llanos, Jean-Pierre .

EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (03)

[6] Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma [J].

Gauvreau, Gail M. ;

Sehmi, Roma ;

Ambrose, Christopher S. ;

Griffiths, Janet M. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (08) :777-792

← 1 →